$Cardiol Therapeutics(CRDL.US)$ NEWS Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024 Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
$Cardiol Therapeutics(CRDL.US)$Cardiol is well positioned to achieve significant milestones in the MAvERIC, ARCHER, and CRD-38 programs during 2024. There is supposedly a data release coming before end of 1H! NFA just thinking outloud!
$Cardiol Therapeutics(CRDL.US)$Cardiol Therapeutics Completes Patient Enrollment in Its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
Trytosaveabit楼主DDDDDDDDDDD:
It’s possible? Needs way more volume! And the spread a bit on the wide side! And with 126K buys, 74K sells but 80K Neutral! That’s 281K give or take! But the volume is 465K? So a lot are getting routed to the dark pool and that’s making it a bit harder to climb as well! But I Truly thank you for the heads up! I really hope it picks up. GL and big profits to ya
$Cardiol Therapeutics(CRDL.US)$Moomoo 24/7· 2 mins ago Cardiol Therapeutics Says FDA Granted Orphan Drug Designation For Its Lead Drug Candidate For Treatment Of Pericarditis
$Cardiol Therapeutics(CRDL.US)$Based on the latest long-term projection bymoneymysticafor CRDL Stock price Forecast 2025 is expected to hit a high price of $6.05 to a low price of $ 4.50 median price of $4.05 throughout the year 2025.
Cardiol Therapeutics股票讨论区
NEWS
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024
Cardiol Therapeutics presented its Phase II ARCHER trial at the World Congress on Acute Heart Failure 2024. The trial is evaluating CardiolRx™ in patients with acute myocarditis. The presentation included the trial design, rationale, and baseline data on the first 50 patients randomized. The ARCHER trial has exceeded 85% of target enrollment, with ...
Cardiol Therapeutics Says FDA Granted Orphan Drug Designation For Its Lead Drug Candidate For Treatment Of Pericarditis
暂无评论